ClinicalTrials.gg

Program

ARO-RAGE

Also written as “ARO-RAGE Injection”.

Its studies are mostly in Asthma, led by Arrowhead Pharmaceuticals.

Furthest: phase 2, since Mar 3, 20223 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals31 open or runningphase 2since Mar 3, 2022Mar 3, 2022Dec 2027phase 2 · NCT07241546

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 3, 2022First study: phase 2 study in AsthmaFirst studyNCT05276570 · 127 enrolled · Australia, New Zealand, Poland and more
  2. Sep 6, 2022Phase 1 study in AsthmaNCT05533294 · 43 enrolled · New Zealand
  3. Nov 17, 2025Phase 2 study in AsthmaNCT07241546 · 36 planned · Canada

Ahead

  1. Dec 2027Primary completion: phase 2 study in AsthmaNCT07241546

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07241546Asthma · Canada2RecruitingDec 202736
NCT05533294Asthma · New Zealand1CompletedFeb 8, 202443
NCT05276570Asthma · Australia, New Zealand, Poland and more2CompletedApr 16, 2025127

How it is read

Names in the registry

  • “ARO-RAGE”, 2 entries
  • “ARO-RAGE Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.